top of page

Lu-177 DOTATATE + Triapine in GEP-NETs

Phase 2 Trial: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors




STATUS: Recruiting

SPONSOR: National Cancer Institute (NCI)

June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study

April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study


This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). 

Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. 

Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

For more information on eligibility criteria, trial locations, study details, etc., go to to view this trial here.

CONTACT/Principal Investigator:

Aman Chauhan, MD




Clinical Trials Using Lutetium Lu 177 Dotatate - NCI

Dr. Chauhan's presentation slides can be downloaded here:

Dr. Chauhan Presentation on Lu-177 DOTATATE + Triapine Trial
Download PPTX • 16.18MB

2023 NANETS Abstract shows the combination of Triapine and Lu-177 DOTATATE was safe with preliminary efficacy signals.

bottom of page